A series of the synthetic protein tyrosine kinase inhibitors known as tyrphostins were studied for their effect on insulin-like growth factor-1 and insulin-stimulated cellular proliferation on NIH-3T3 fibroblasts overexpressing either receptor, as well as for their ability to inhibit ligand-stimulated receptor autophosphorylation and tyrosine kinase activity toward exogenous substrates. Several of the tyrphostins tested demonstrated a dramatic effect by inhibiting hormone-stimulated cell proliferation, with IC 50 s in the submicromolar range, while being unable to block serum-stimulated cell proliferation. The tyrphostins also inhibited receptor autophosphorylation and tyrosine kinase activity, with a higher IC 50 , in the micromolar range. Most of the tyrphostins tested presented no clear preference for either receptor, although two of them (AG1024 and AG1034) showed significantly lower IC 50 s for IGF-1 than for insulin receptors. These results suggest that, in spite of the high homology of the kinase regions of both receptors, it could be possible to design and synthesize small molecules capable of discriminating between them. The synthesis of such specific inhibitors could be an excellent tool to establish the precise signalling mechanisms that distinguish between the different effects of these two hormones.
tyrosine kinase activity, with a higher IC 50 , in the micromolar range. Most of the tyrphostins tested presented no clear preference for either receptor, although two of them (AG1024 and AG1034) showed significantly lower IC 50 s for IGF-1 than for insulin receptors. These results suggest that, in spite of the high homology of the kinase regions of both receptors, it could be possible to design and synthesize small molecules capable of discriminating between them. The synthesis of such specific inhibitors could be an excellent tool to establish the precise signalling mechanisms that distinguish between the different effects of these two hormones. (Endocrinology 138: 1427-1433, 1997) T HE INSULIN-LIKE growth factor-1 (IGF-1) receptor is a member of the tyrosine kinase receptor family, which includes among others the insulin, epidermal growth factor (EGF), nerve growth factor (NGF), and platelet-derived growth factor (PDGF) receptors. Insulin and IGF-1 receptors are highly homologous, heterotetrameric molecules composed of two extracellular ␣-subunits with binding capacity and two transmembrane ␤-subunits with tyrosine kinase activity that are activated in response to ligand binding (1, 2) . Thus, binding of the hormone to its respective receptor triggers a cascade of events that includes receptor autophosphorylation, phosphorylation of intracellular substrates, and activation of signaling pathways involved in metabolic processes and growth regulation.
Both peptide hormones induce pleiotropic responses in many cell types and share a host of common functions. However, in spite of their high degree of homology, the principal role of insulin under normal physiological conditions is to maintain metabolic homeostasis, whereas IGF-1 stimulates growth and differentiation (3) . Accordingly, with its role in cell growth, overexpression of IGF-1 receptors confers tumorigenic potential to cells (4, 5) as well as protection from apoptosis (5-7).
The first event in the signal transduction cascade of both insulin and IGF-1 is the autophosphorylation of their respective receptors. The importance of receptor autophosphorylation on the subsequent cellular actions of the hormones remains controversial. Several lines of evidence have suggested that tyrosine phosphorylation of the insulin receptor may not be essential for all of its functions (8, 9) . Similarly, high levels of autophosphorylation are not required for mediation of all the biological activities of the IGF-1 receptor (10, 11) . However, mutant IGF-1 receptors with decreased autophosphorylation present severely impaired mitogenic and tumorigenic activities (4, 11) . Thus, autophosphorylation and tyrosine kinase activity of those receptors play an important role in their signaling functions. Accordingly, enhanced activity of tyrosine kinases has been implicated in many cancers and other proliferative diseases (12) . Tyrosine kinases and the signaling pathways in which they participate have therefore been identified as potential targets for drug design. The tyrphostins are a family of synthetic protein tyrosine kinase inhibitors that selectively inhibit receptor autophosphorylation (13) and represent an excellent tool to examine receptor function. The tyrphostins are derived from a benzylidene malononitrile nucleus, which resembles the phenolic group of tyrosine, with additional substitutions. Many of these substitutions have resulted in different compounds that inhibit specific tyrosine kinases (Table 1) . In this report, we have evaluated several tyrphostins for inhibition of the tyrosine kinase activity of the IGF-1 and insulin receptors, as well as for their effect on cell proliferation in response to their respective ligands.
Materials and Methods Tyrphostins
Tyrphostins AG825 (14) , AG1024, AG1034, AG1049 (15) , and AG1557 (16) were prepared as described previously. Tyrphostin AG1500 will be described in a forthcoming publication.
Cell culture
NIH-3T3 mouse fibroblast cells overexpressing wild-type IGF-1 (clone NWTc43) or insulin receptors (clone WT2) were previously described (10, 17) . Cells were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin, in the presence of 500 g/ml G418 (Geneticin, Life Technologies, Gaithersburg, MD), in a humidified atmosphere of 95% air and 5% CO 2 at 37 C.
MTT cellular proliferation assays
MTT assays were performed as described (4) . NIH-3T3 cells overexpressing IGF-1 or insulin receptors were plated on 96-well plates (2,000 -5,000 cells/well) and maintained overnight in complete medium. Cells were then changed to DMEM containing 1% FBS in the absence or presence of 10 Ϫ8 m IGF-1 or insulin and the different tyrphostins in triplicate wells (four different concentrations ranging from 0.1-5 m), for 6 days (120 h). Medium was replaced every 48 h. At the indicated periods of time, the medium was aspirated from the wells and 100 l MTT reagent (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide, Sigma Chemical Co., St. Louis, MO) were added to each well. The cells were then incubated for 4 h at 37 C and lysed by addition of 100 l isoamylic alcohol and shaking for 20 min. Plates were then read in a In parallel, direct counting of the cells attached to the plate was performed. After treatment, medium was removed and plates were washed twice with 1 ϫ PBS. Cells remaining attached to the plate were trypsinized and counted in a Neuebauer chamber.
Intact cell tyrosine phosphorylation
Tyrosine phosphorylation of the ␤-subunits of the IGF-1 and insulin receptors was analyzed in total cell lysates by immunoblotting with an antiphosphotyrosine antibody as described (11) . Briefly, confluent cells in 60-mm plates were incubated overnight in serum-free (SF) medium (DMEM with 1% BSA and 20 mm HEPES, pH 7.5). Tyrphostins at different concentrations were added in fresh SF-medium for 1 h. Cells were then stimulated with 10 Ϫ8 m IGF-1 or insulin for 1 min. After treatment, cells were washed twice with ice-cold 1 ϫ PBS and lysed in the presence of 50 mm HEPES, pH 7.9, 100 mm NaCl, 10 mm EDTA, 1% Triton X-100, 4 mm sodium pyrophosphate, 2 mm sodium orthovanadate, 1 mm phenylmethylsulphonyl fluoride and 10 mm sodium fluoride. Lysates were cleared by centrifugation and equal amounts of protein were separated by a 7.5% SDS-PAGE and transferred to a nitrocellulose membrane (Protran, Schleicher & Schuell, Keene, NH). Tyrosine phosphorylated proteins were immunoblotted with monoclonal antiphosphotyrosine antibody (clone 4G10, Upstate Biotechnology Inc., Lake Placid, NY) and detected with horseradish peroxidase-conjugated secondary antibody using an ECL system (Amersham Life Sciences, Arlington Heights, IL). The autoradiograph films were then scanned and analyzed by densitometry using the NIH Image program (version 1.57).
Receptor semipurification
Semipurification of solubilized IGF-1 and insulin receptors was performed as described (11) with some modifications. Briefly, confluent NIH-3T3 cells overexpressing IGF-1 or insulin receptors were washed twice with ice-cold 1 ϫ PBS and lysed in the presence of 50 mm HEPES, pH 7.6, 150 mm NaCl, 1% Triton X-100, 1 mm phenylmethylsulfonyl fluoride and 100 U/ml bacitracin. Lysates were cleared by centrifugation, and the supernatants were recycled three times through a disposable polypreparative column packed with 2 ml of wheat germ agglutinin (WGA) bound to agarose (Vector Laboratories, Burlingame, CA). The column was washed with 100 ml of a buffer containing 50 mm HEPES, pH 7.6, 150 mm NaCl and 0.1% Triton X-100. Glycoproteins were eluted from the column with the same buffer supplemented with 0.3 m N-acetyl-d-glucosamine.
Phosphorylation of exogenous substrates
Tyrosine kinase activity of the semipurified receptors was assayed as described (11) with minor modifications. Briefly, aliquots of the WGA eluate were incubated overnight at 4 C in the presence or absence of 10 Ϫ8 m IGF-1 or insulin and the different tyrphostins, in a final volume of 40 l, with 50 mm HEPES buffer (pH 7.6) supplemented with 100 mm NaCl, 0.04% Triton X-100, and 0.01% BSA. Phosphorylation was allowed to begin by addition of 60 l kinase buffer (1 mg/3 ml exogenous substrate poly(Glu:Tyr) 4:1 , 1.5 mm CTP, 75 mm MgCl 2 , 75 m ATP, and 5 Ci/ sample ␥ 32 P-ATP). The reaction was stopped by spotting 70 l of the reaction mixture onto 3 ϫ 3 cm Whatman 3MM filter paper squares and washing them in 10% trichloroacetic acid and 10 mm sodium pyrophosphate. Papers were then air-dried and counted in a ␤-counter with scintillation liquid.
Results

Cellular proliferation
Different tyrphostins (Table 1) were tested for their ability to inhibit IGF-1-stimulated cell proliferation of NIH-3T3 fibroblasts overexpressing IGF-1 receptors (NWTc43 clone). The MTT assay was used to that end. Several of the tyrphostins displayed a dramatic effect, almost completely blocking IGF-1-stimulated cell growth at doses as low as 5 m (Fig. 1) . Table 2 shows the IC 50 values for several of the more potent tyrphostins used in the study. The MTT assay measures mitochondrial activity, which under normal circumstances correlates with cell number. To ascertain that tyrphostins were not affecting cellular respiration and slowing metabolism only, thereby resulting in an underestimation of the cell number, we manually performed cell counts in a parallel study. Cell counts gave similar results to the MTT assays (data not shown), thus indicating that tyrphostins were really inhibiting cell proliferation. The tyr- phostins were also assayed for their ability to block serumstimulated cellular proliferation (in the presence of 10% FBS). Under these conditions, only AG1557 showed a significant effect decreasing the rate of serum-stimulated cell proliferation with an IC 50 of 5.3 Ϯ 0.2 m, whereas all the other tyrphostins tested did not affect the rates of cellular proliferation (data not shown).
The tyrphostins were then tested in NIH-3T3 cells overexpressing insulin receptors (WT2 clone). The results obtained were comparable to those observed with the cells overexpressing IGF-1 receptors ( Table 2) . As was expected, insulin receptor overexpressing cells, showed a much slower proliferation rate than IGF-1 receptor overexpressing cells. In a typical experiment, IGF-1 receptor overexpressing cells would increase their number 20-fold in 6 days, whereas insulin receptor overexpressing cells multiply only by a factor of 5 in the same time period (Figs. 1 and 2 ). The effect of the tyrphostins on cellular proliferation in cells overexpressing insulin receptors was similar to that described on cells overexpressing IGF-1 receptor (Fig. 2) . Tyrphostins AG1024, AG1034, and AG1557 all presented IC 50 doses on the 10 Ϫ7 m range. When tested in their ability to block serum-stimulated cell proliferation, only AG1557 significantly decreased it, whereas all the other tyrphostins tested did not alter the rates of cell growth (data not shown).
Receptor autophosphorylation and tyrosine kinase activity
Receptor autophosphorylation assays were then performed in intact cells. A time-course experiment (Fig. 3) determined that 1 h incubation was the optimal time point of tyrphostin effect. The inhibition of the receptor autophosphorylation by the different tyrphostins tested was transient, with a complete recovery of normal autophosphorylation levels seen after 12 h of incubation with the inhibitors. This is possibly due to the metabolism of the compounds, as indicated by the loss of the orange coloration they give to the culture medium. Nevertheless, the effect of the tyrphostins on cellular proliferation was not affected by these changes and persisted at least until the subsequent doses were added at 48-h intervals. The different tyrphostins were then assayed in a dose-response manner after 1-h incubation. A typical experiment for NWTc43 cells is shown in Fig. 4a . The IC 50 of the tyrphostins were significantly higher for inhibiting IGF-1 receptor autophosphorylation than for the inhibition of cellular proliferation (Table 2) . Tyrphostins AG825 and AG1500 were also tested, showing no significant effect on the IGF-1 receptor autophosphorylation.
Insulin receptor autophosphorylation was also tested (Fig.  4b) . As with IGF-1 receptors, the IC 50 dose was higher than the one needed to inhibit insulin-stimulated cellular proliferation. Some of the tyrphostins assayed, particularly AG1024 and AG1034, showed a degree of preference of IGF-1 vs. insulin receptors with regard to inhibition of ligandstimulated receptor autophosphorylation (Table 2) . Tyrphostins AG825 and AG1500 did not affect insulin receptor autophosphorylation.
A number of the tyrphostins were then tested for their ability to inhibit tyrosine kinase activity of the receptors toward exogenous substrates in vitro. The IC 50 values for tyrosine kinase inhibition were also on the micromolar range (Table 2) . Again, tyrphostins AG1024 and AG1034 showed the highest degree of discernment between insulin and IGF-1 receptors with regard to inhibition of ligand-stimulated tyrosine kinase activity of the receptor (Fig. 5 ).
Discussion
Protein phosphorylation plays an essential role in the control of cellular metabolism and growth. Tyrosine phosphorylation in particular has been shown to be an important regulator of the activity of oncogene products. Growth factors acting in an autocrine or paracrine manner can cause persistently enhanced tyrosine kinase activity which in turn leads to various disease states (12) . Enhanced tyrosine kinase activity has been thus implicated in many cancers and other proliferative disorders as well as in nonmalignant proliferative diseases, including psoriasis (18) and atherosclerosis (19) .
The IGF-1 receptor belongs to the family of receptor tyrosine kinases. IGF-1 effects multiple functions in different cell types, but is primarily involved in cell growth and differentiation (3). Accordingly, IGF-1 receptor levels have been correlated with tumorigenic potential of the cells (4, 5) , and increased IGF-1 receptor mRNA has also been detected in malignant states, such as Wilms tumor (20) . Moreover, IGF-1 is also able to act as survival factor, preventing apoptosis in a number of cell types (6, 7, 21, 22) .
Tyrosine kinases and the signaling pathways in which they participate have therefore been identified as potential targets for drug design with therapeutic purposes. Along this line of interest, tyrphostins are a series of protein tyrosine kinase inhibitors that were originally modeled after the microbial inhibitor erbstatin (23) . These compounds were derived from the benzylidene malononitrile nucleus, resembling the phenolic group of tyrosine, with additional substitutions directed to increase their biological activity. Some of these substitutions resulted in significant discrimination among tyrosine kinases (13) . Different groups of tyrphostins that are highly discriminating among particular growth factors have been described so far. Specific tyrphostins against NGF have been shown to block NGF-induced phospholipase C-␥ (PLC-␥) phosphorylation, phosphatidylinositol 3Ј kinase activation, and neurite outgrowth in PC12 cells (15) . Tyrphostins against PDGF inhibited PDGF receptor kinase and PDGF-dependent DNA synthesis in Swiss 3T3 cells and porcine aorta endothelial cells (24) . Effects of tyrphostins on EGF-mediated functions have been widely studied. Tyrphostins against EGF inhibited EGF-dependent phosphorylation of exogenous substrates and cellular proliferation (14, 16, 23) as well as EGF-dependent activation of the src-family kinases (25) , with IC 50 s in the submicromolar or micromolar range. Recently, a tyrphostin blocking Jak-2 activity and cell growth in leukaemic cells both in vitro and in vivo has been described (26) , with important implications for cancer control and treatment. In this report, we tested the effect of several tyrphostins on the IGF-1-and insulin-stimulated cellular proliferation, as well as autophosphorylation in intact cells and tyrosine kinase activity toward exogenous substrates in vitro.
Several of the tyrphostins tested dramatically blocked hormone-stimulated cellular proliferation. Low doses of the inhibitor (in the 10 Ϫ6 m range) were enough to completely block the effect of the ligand, with the IC 50 for most of the inhibitors being in the 10 Ϫ7 m range. On the other hand, the IC 50 concentrations needed to block the autophosphorylation and tyrosine kinase activity of the receptors were about 10-fold higher. Despite these differences, the effect of the tyrphostins on cellular proliferation is specific for IGF-1 and insulin receptors because the inhibitory effect on seruminduced proliferation is negligible for all tyrphostins tested except AG1557 (data not shown). Interestingly, a similar result was found with tyrphostins inhibiting EGF receptordependent tyrosine kinase activity and [
3 H]thymidine incorporation (14) Moreover, other well known tyrosine kinase inhibitors such as genistein and erbstatin inhibit EGF-induced [ 3 H]thymidine uptake at far lower concentrations than those needed to inhibit tyrosine phosphorylation in intact cells (27, 28) . One possible explanation is that, in addition to inhibiting the IGF-1 and insulin receptor tyrosine kinase activities, the tyrphostins inhibit some downstream tyrosine kinase governing cellular proliferation, the activation of which is IGF-1-and insulin-dependent.
Most of the tyrphostins tested showed no distinct specificity distinguishing between insulin and IGF-1 receptors, except for AG1024 and AG 1034, which showed a tendency to lower IC 50 s for the IGF-I than the insulin receptors.This difficulty in finding specific inhibitors is not unusual in view of the strict evolutionary conservation of the tyrosine kinase domain and the high degree of homology of the ATP-binding region of both receptors. It has been proposed by the use of computer simulations that tyrphostins bind to the active center of the receptors, distorting it in such a way that in most cases neither the substrate nor ATP can bind to the receptor (29) . In that case, the presence of the different substituents in the benzylidene malononitrile nucleus can make possible the design of inhibitors capable of fine discrimination among receptors.
We have identified a family of tyrphostins that inhibit IGF-1 and insulin receptor autophosphorylation and function. Interestingly, the two tyrphostins that showed the highest activities in our system (AG1024 and AG1034) have been previously assayed for their effects in blocking NGF function   FIG. 4 . Dose-response of tyrphostin inhibition of IGF-1 (A) and insulin (B) receptor autophosphorylation in intact NWTc43 and WT2 cells respectively. Cells were maintained overnight in SF-medium and then incubated for 1 h in the presence of the indicated concentrations of tyrphostins. IGF-1 (10 Ϫ8 M) or insulin (10 Ϫ8 M) were then added in fresh media and the cells were stimulated for 1 min. Following stimulation cells were lysed and the lysates were analyzed by phosphotyrosine immunoblotting as described under Materials and Methods. (15) , showing no distinct effect. Conversely, during this study we also tested tyrphostin AG825, which has been shown to act against the EGF receptor (14), finding it to be inactive with IGF-1 and insulin receptors.
In addition to the potential therapeutic uses of receptorspecific tyrphostins, the ultimate design of specific insulin and IGF-1 receptor kinase inhibitors may also help to establish the precise signaling mechanisms that discriminate between the different effects of these two hormones, which at the present time have not been clearly elucidated. 
